Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers

NCT05593419 is registered in ClinicalTrials.gov with Peking University as lead sponsor.

NCT NCT05593419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05593419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Selecting Patients Who May Benefit From Immunotherapy by Tissue-based Biomarkers
Lead sponsor
Peking University
Phase
Observational
Overall status
Unknown status
Start date
October 31, 2022
Completion date
October 31, 2025
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer patients received immunotherapy